6YIO image
Entry Detail
PDB ID:
6YIO
Keywords:
Title:
CRYSTAL STRUCTURE OF FAB RG6292 IN COMPLEX WITH CD25 ECD
Biological Source:
Source Organism:
Host Organism:
PDB Version:
Deposition Date:
2020-04-01
Release Date:
2020-11-11
Method Details:
Experimental Method:
Resolution:
1.83 Å
R-Value Free:
0.23
R-Value Work:
0.20
R-Value Observed:
0.20
Space Group:
P 1 21 1
Macromolecular Entities
Polymer Type:polypeptide(L)
Description:Interleukin-2 receptor subunit alpha
Chain IDs:A (auth: B)
Chain Length:203
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:FAB FRAGMENT HEAVY CHAIN
Chain IDs:B (auth: H)
Chain Length:227
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Description:FAB FRGAMENT LIGHT CHAIN
Chain IDs:C (auth: L)
Chain Length:214
Number of Molecules:1
Biological Source:Homo sapiens
Primary Citation
CD25-T reg -depleting antibodies preserving IL-2 signaling on effector T cells enhance effector activation and antitumor immunity.
Nat Cancer 1 1153 1166 (2020)
PMID: 33644766 DOI: 10.1038/s43018-020-00133-0

Abstact

Intratumoral regulatory T cell (Treg) abundance associates with diminished anti-tumor immunity and poor prognosis in human cancers. Recent work demonstrates that CD25, the high affinity receptor subunit for IL-2, is a selective target for Treg depletion in mouse and human malignancies; however, anti-human CD25 antibodies have failed to deliver clinical responses against solid tumors due to bystander IL-2 receptor signaling blockade on effector T cells, which limits their anti-tumor activity. Here we demonstrate potent single-agent activity of anti-CD25 antibodies optimized to deplete Tregs whilst preserving IL-2-STAT5 signaling on effector T cells, and demonstrate synergy with immune checkpoint blockade in vivo. Pre-clinical evaluation of an anti-human CD25 (RG6292) antibody with equivalent features demonstrates, in both non-human primates and humanized mouse models, efficient Treg depletion with no overt immune-related toxicities. Our data supports the clinical development of RG6292 and evaluation of novel combination therapies incorporating non-IL-2 blocking anti-CD25 antibodies in clinical studies.

Legend

Protein

Chemical

Disease

Primary Citation of related structures